SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

Why It Matters

Mavacamten offers the first FDA‑supported pharmacologic option for symptomatic pediatric obstructive HCM, potentially reducing the need for invasive myectomy and altering long‑term disease trajectory. This could reshape treatment guidelines and open a new market segment for cardiac myosin inhibitors.

Key Takeaways

• Trial enrolled 44 adolescents, ages 12‑17
• Mavacamten cut LVOT gradient ~50 mm Hg vs placebo
• No ejection‑fraction decline; safety similar to placebo
• LV wall thickness reduced 2 mm, placebo increased 1 mm
• 85% on beta‑blockers; drug added to background therapy

Pulse Analysis

Hypertrophic cardiomyopathy is the most common inherited heart disorder, yet pediatric‑onset cases—estimated at three to nine per 100,000 children—have long lacked approved drug therapies. Historically, clinicians relied on beta‑blockers, calcium‑channel blockers, or surgical myectomy to manage obstruction, often with mixed results. The SCOUT‑HCM trial fills a critical gap by targeting adolescents, a demographic where disease severity typically exceeds adult presentations, and by providing rigorous, double‑blind data that can inform future guideline updates.

In the study, participants received weight‑adjusted mavacamten doses of 2 or 5 mg daily alongside standard background therapy. By week 28, the drug lowered Valsalva LVOT gradients from an average of 78 mm Hg to roughly 30 mm Hg, a statistically significant improvement (P < 0.0001). Secondary endpoints—including resting gradients, maximal wall thickness, and NT‑proBNP levels—also trended favorably, while echocardiographic ejection fraction remained above 50 %. Adverse events were rare and comparable to placebo, reinforcing the drug’s safety profile in a high‑risk youth cohort.

For Bristol Myers Squibb, these results pave the way for an FDA label expansion that could capture a previously untapped pediatric market. A long‑term extension study is already underway, suggesting that sustained hemodynamic benefits may translate into decades of reduced morbidity. The trial also signals a broader shift toward pediatric‑focused cardiovascular research, encouraging pharmaceutical innovators to pursue age‑specific trials rather than extrapolating adult data. As insurers and providers evaluate cost‑effectiveness, mavacamten could become a cornerstone therapy that reshapes the natural history of obstructive HCM from childhood onward.